Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease
Status:
Completed
Trial end date:
2004-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the effects of IL2 receptor antibody (also known as
Daclizumab or Zenapax) and corticosteroids alone for control of GVHD. Treatment with
corticosteroids is standard care for GVHD. This research is being done because the
investigators do not know whether addition of this new medication to standard corticosteroid
therapy improves response rates. Since Zenapax binds to a type of cell which is thought to
cause GVHD and possibly inactivates them, investigators have reason to believe that addition
of Zenapax night result in better control of GVHD This study will determine whether the
addition of another medication, Zenapax, will be more effective than steroids alone in
suppressing GVHD and improving symptoms of GVHD.
Daclizumab (Zenapax) is approved by the Food and Drug Administration (FDA) for use in patient
with kidney transplant to help prevent graft rejection. This medication has been used in bone
marrow transplant patients to treat GVHD.